米乐m6
米乐m6:About Henlius
米乐m6:Company Profile
米乐m6:Corporate Culture
Honor
米乐m6:Board of Directors
Management Team
Advisory Committee
Product
米乐m6:Marketed Products
Products in R&D
Clinical Trial
米乐m6:Science & Technology
米乐m6:R&D Result
米乐m6:Innovation Centre
米乐m6:Technology Platform
Quality Management
Manufacturing
Collaborations
米乐m6:Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
Stock Info
米乐m6:IR Calendar
Investor Presentation
米乐m6:Analyst Coverage
Contact Information
Media
Press Release
米乐m6:Multi-media
Media Reports
米乐m6:Media Enquiry
Careers
米乐m6:Talent Philosophy
米乐m6:Staff Life
米乐m6:Training and Development
Contact Us
Contact Information
Customer Message
Privacy
米乐m6:Legal Statement
Compliance
EN
简体
EN
繁體
Home
About Henlius
Company Profile
Corporate Culture
Honor
米乐m6:Board of Directors
Management Team
米乐m6:Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
米乐m6:Quality Management
米乐m6:Manufacturing
Collaborations
Investor Relations
Information Disclosure
Listing Documents
米乐m6:Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
米乐m6:Contact Information
Media
米乐m6:Press Release
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
米乐m6:Popular Science
米乐m6:Media Reports
米乐m6:Media Enquiry
Careers
Talent Philosophy
米乐m6:Staff Life
Training and Development
米乐m6:Job Opportunities
Contact Us
米乐m6:Contact Information
Customer Message
Privacy
Legal Statement
Compliance
Be the most trusted biotech company
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
米乐m6:Multi-media
Company
米乐m6:Popular Science
米乐m6:Highlights
Download
Media Reports
米乐m6:Media Enquiry
2022-12-27
Henlius and Fosun Pharma Entered into an Exclusive License Agreement for HANSIZHUANG in the US
2022-12-15
First Patient Dosed in a Phase 1 Clinical Study of Henlius Novel Anti-GARP and Anti-PD-1 Dual mAb Therapy in Australia
2022-12-15
HANSIZHUANG Granted Orphan Drug Designation in the European Union for Small Cell Lung Cancer
2022-12-09
First Patient Dosed in the Phase 1 Clinical Trial of Henlius’ Novel Anti-TIGIT Fc Fusion Protein HLX53
2022-12-05
Consul General in San Francisco visited Henlius US Innovation Centre
2022-12-02
The Phase 3 Clinical Study Results of Novel Anti-PD-1 mAb Serplulimab for the First-Line Treatment of ESCC Released at ESMO Asia Congress 2022
2022-12-02
The Updated Results of Phase 3 Clinical Study of Novel Anti-PD-1 mAb Serplulimab for the First-Line Treatment of ES-SCLC Released at ESMO Asia Congress 2022
2022-12-02
First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Novel Anti-GARP mAb HLX60
2022-11-29
First Patient dosed in a Head-to-Head First-Line Bridging Study of HANSIZHUANG for ES-SCLC treatment in the US
1
2
3
...
7
var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?90c4d9819bca8c9bf01e7898dd269864"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })(); !function(p){"use strict";!function(t){var s=window,e=document,i=p,c="".concat("https:"===e.location.protocol?"https://":"http://","sdk.51.la/js-sdk-pro.min.js"),n=e.createElement("script"),r=e.getElementsByTagName("script")[0];n.type="text/javascript",n.setAttribute("charset","UTF-8"),n.async=!0,n.src=c,n.id="LA_COLLECT",i.d=n;var o=function(){s.LA.ids.push(i)};s.LA?s.LA.ids&&o():(s.LA=p,s.LA.ids=[],o()),r.parentNode.insertBefore(n,r)}()}({id:"K9y7iMpaU8NS42Fm",ck:"K9y7iMpaU8NS42Fm"});
米乐m6登录 - m6平台 - 米乐m6
米乐m6 - 米乐m6登陆
米乐m6app下载
米乐m6平台 - 官方下载 - 米乐m6在线登录
一分赛车_米乐m6_一分赛车官网